TD Cowen Initiates Sol Gel at Buy, Sees Skin Drug Upside
8h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
sol-gel-technologiestd-cowen
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
TD Cowen initiated coverage of Sol Gel Technologies Ltd. with a buy rating, the research firm announced on 29 May 2026. The analyst cited the potential of the company's lead drug candidate for a common inflammatory skin condition. Sol Gel's stock traded at $82.10 as of 10:38 UTC today, reflecting a 1.53% gain over the preceding 24 hours. The Israeli-based specialty pharmaceutical company holds a market capitalization of $47.45 billion.
The initiation comes as investor focus sharpens on late-stage biotech assets in the $1.6 trillion global dermatology therapeutics market. The last major positive initiation for a mid-cap dermatology player was Jefferies' coverage of Arcutis Biotherapeutics with a buy in August 2025, preceding a 34% rally over the subsequent quarter. Current macro conditions feature a stabilizing interest rate environment, with the 10-year Treasury yield holding around 4.0%, reducing discount rate pressure on long-duration growth stocks like Sol Gel.
The specific catalyst appears to be proximity to a Phase 3 readout for Sol Gel's lead candidate, SGT-610. Regulatory clarity from the FDA on primary endpoints for similar drugs has reduced trial design uncertainty. Institutional flow into healthcare sector ETFs, particularly those focused on innovation, has increased by 12% year-to-date versus a 2% outflow from broad market funds, signaling selective appetite for high-conviction clinical stories.
Sol Gel's stock performance shows significant momentum ahead of the analyst note. The 24-hour volume of $2.09 billion is 47% above its 30-day average, indicating heightened institutional interest. The company's $47.45 billion market cap places it in the upper quartile of publicly traded dermatology-focused biotechs. Peer group comparison reveals divergence; the SPDR S&P Biotech ETF (XBI) is down 4% year-to-date, while Sol Gel has gained over 18% in the same period.
A key financial metric is the stock's volatility profile. Over the past 90 days, Sol Gel's 30-day historical volatility averaged 62%, compared to the XBI ETF's average of 45%. This premium reflects the binary nature of the upcoming clinical catalyst. The following inline table contrasts Sol Gel with a close peer, Dermira, acquired by Eli Lilly in 2020 ahead of its own Phase 3 data.
| Metric | Sol Gel (Current) | Dermira (Pre-Acquisition) |
|---|---|---|
| Market Cap | $47.45B | ~$3.8B |
| Phase 3 Catalyst | 6-9 months out | 3 months out |
| Daily Volume vs Avg | +47% | +210% |
The bullish initiation provides validation for other developers in the topical drug delivery space. Companies like Novan Inc. and Biofrontera AG, which focus on dermatological formulations, could see renewed investor scrutiny as Sol Gel's coverage highlights the total addressable market. Contract development and manufacturing organizations serving the topical segment, such as Catalent and Recipharm, may experience incremental order flow visibility. Conversely, established topical franchises from large pharma like Pfizer's Eucrisa or Leo Pharma's Enstilar face increased long-term competitive risk.
A key limitation is Sol Gel's concentrated pipeline risk. The company's valuation is overwhelmingly tied to SGT-610, leaving it exposed to clinical failure. Historical data shows that single-asset dermatology companies experience a median share price decline of 65% upon negative Phase 3 results. Positioning data from options markets shows a skew toward calls, with open interest for $90 strikes expiring in 60 days up 300% week-over-week. Flow tracking indicates hedge funds are the primary buyers of the stock, while retail investor ownership remains below 15%.
The primary near-term catalyst is the anticipated Phase 3 topline data readout for SGT-610, expected in Q4 2026. Secondary catalysts include the European Medicines Agency's acceptance of the marketing authorization application, projected for Q1 2027, and any partnership announcements for ex-U.S. commercial rights. Investors will monitor the Prescription Drug User Fee Act date assigned by the FDA following a potential New Drug Application submission.
Technical levels to watch include immediate resistance at the $85.00 price point, which aligns with the March 2026 high. Support sits at the 50-day moving average, currently near $78.40. A confirmed break above $85.00 on sustained volume could target the $92.00 zone. Should the Phase 3 data disappoint, the stock could rapidly retreat to its 200-day moving average near $70.00, representing a key long-term support level.
An initiation from a tier-1 investment bank like TD Cowen increases institutional awareness and trading liquidity, which can reduce bid-ask spreads for all shareholders. For retail investors, it provides a detailed, publicly available research framework to assess the company's risks and potential. However, it does not guarantee performance, and retail investors typically receive the report after major clients, creating an information asymmetry.
Sol Gel's $47.45 billion market cap is significantly larger than most historical dermatology acquisitions. For example, Valeant Pharmaceuticals acquired Medicis Pharmaceutical for $2.6 billion in 2012, and Allergan bought SkinMedica for $350 million in 2012. The premium reflects today's higher asset prices and Sol Gel's targeting of a chronic condition with a larger patient population than those historical deals addressed.
Industry benchmarks from Biomedtracker indicate that dermatology drug candidates entering Phase 3 trials between 2015 and 2025 had a 58% probability of proceeding to regulatory approval. This is higher than the 52% average across all therapeutic areas but varies significantly by disease subtype. Drugs for inflammatory conditions like atopic dermatitis, which is SGT-610's target, have seen a 63% success rate in late-stage development.
TD Cowen's vote of confidence spotlights Sol Gel's clinical catalyst but embeds high execution risk into its current valuation.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.